IP Library Granted Patent US 7,205,114
Granted Patent B2
US 7,205,114 · App. 10/846,380 · Granted Apr 17, 2007

Oxidized fungal antigens and methods of making and using thereof

Assignee: Focus Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,205,114
App. No.
10/846,380
Granted
Apr 17, 2007
Kind
B2
Abstract

The present invention relates to oxidized fungal antigens and methods of making and using thereof. More particularly, the present invention provides a method for producing an oxidized fungal antigen in culture filtrate. The present invention also provides for the produced oxidized fungal antigens. Devices comprising such oxidized fungal antigens, methods for testing for fungal antibodies using the oxidized fungal antigens and methods for producing anti-fungal antibodies using oxidized fungal antigens are further provided. Antigen detection devices comprising anti-fungal antibodies raised against oxidized fungal antigens produced by the present methods are further provided.

Claims (12)

1. A method of testing a sample to determine the presence and/or amount of an antibody to a fungal antigen, the method comprising:

a) contacting the fungal antigen with an oxidizing agent in a suitable device to produce an oxidized fungal antigen attached to the surface of the device, wherein said oxidized fungal antigen attached to said device is suitable for testing an antibody to the fungal antigen;

b) contacting a sample suspected of containing an antibody to a fungus with the device containing the attached oxidized fungal antigen produced in step b) under suitable conditions to allow binding of the antibody, if present in the sample, to the oxidized fungal antigen; and

c) assessing binding between the antibody and the oxidized fungal antigen to determine the presence and/or amount of the antibody in the sample.

2. The method of claim 1 , wherein said fungal antigen is a pathogenic fungus.

3. The method of claim 1 , wherein the sample is a clinical sample.

4. The method of claim 3 , wherein the sample is a human clinical sample.

5. The method of claim 1 , wherein the fungal antigen has not been purified from the culture filtrate.

6. The method of claim 1 , wherein the oxidizing agent is periodate.

7. The method of claim 1 , wherein the binding between the antibody and the oxidized fungal antigen is assessed by a sandwich or competitive assay format.

8. The method of claim 1 , wherein the binding between the antibody and the oxidized fungal antigen is assessed by a format selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA), immunoblotting, immunoprecipitation, radioimmunoassay (RIA), immunostaining, latex agglutination, indirect hemagglutination assay (IHA), complement fixation, indirect immnunofluorescent assay (FA), nephelometry, flow cytometry assay, chemiluminescence assay, lateral flow immunoassay, u-capture assay, inhibition assay and avidity assay.

9. The method of claim 1 , wherein the binding between the antibody and the oxidized fungal antigen is assessed by an ELISA format.

Assignments (2)
CHANGE OF NAME Recorded Sep 11, 2017
From: FOCUS DIAGNOSTICS, INC.
To: QUEST DIAGNOSTICS INFECTIOUS DISEASE, INC.
Reel/Frame 043811/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2004
From: PRINCE, HARRY; SU, XIN; KONG, LILLY; NGO, CELINE (DEVOR) (HEIR TO KEN DEVOR, DECEASED); ARAKELOV, SERGEI; HOGREFE, WAYNE
To: FOCUS TECHNOLOGIES, INC.
Reel/Frame 015486/0145 →
Continuity (2)
Continuation In Part 1002818100 · Dec 21, 2001
Related Publication 20050112708A1 · May 26, 2005